You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 147 No. 12, December 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  REVIEW ARTICLE
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (205)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Nonsteroidal Anti-inflammatory Drug Gastropathy

Recognition and Response

Sanford H. Roth, MD; Ralph E. Bennett, MD

Arch Intern Med. 1987;147(12):2093-2100.


Abstract

• Gastropathy, recognized as gastric lesional disease ranging from erosions to actual ulcer craters, represents the most ubiquitous significant complication of common nonsteroidal anti-inflammatory drug (salicylate and nonsalicylate) use. Recently, this association has been established as distinct from classic peptic ulcer disease, which is primarily acidmediated, duodenal, and more prevalent in a younger, often male, population. Nonsteroidal anti-inflammatory drug gastropathy is usually antral/prepyloric disease, and research indicates it is mediated through blockade of cyclooxygenase with reduction in cytoprotective gastric prostaglandins. The previous literature has been confounded with short-term studies on healthy volunteers and animals that emphasize the resiliency of normal gastric adaptation to heal such gastropathy. Newer long-term studies in patients with arthritis undergoing anti-inflammatory therapy on a sustained basis indicate fatigue of normal adaptation, with persisting gastropathy leading to bleeding and even death. In addition, silent lesions are more common as symptomatology is not synchronous with lesional disease. Since endoscopy is an expensive, not always utilized procedure, it is important to identify the population most at risk for appropriate cytoprotective management as well as modification of the anti-inflammatory therapy program.

(Arch Intern Med 1987;147:2093-2100)



Author Affiliations

From the Arthritis Center Ltd/Arizona Institute, Phoenix.


Footnotes

Accepted for publication Aug 31, 1987.

Reprint requests to Arthritis Center Ltd/Arizona Institute, 3330 N Second St, Suite 601, Phoenix, AZ 85012 (Dr Roth).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy and Safety of a Topical Diclofenac Solution (Pennsaid) in the Treatment of Primary Osteoarthritis of the Knee: A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial
Roth and Shainhouse
Arch Intern Med 2004;164:2017-2023.
ABSTRACT | FULL TEXT  

Helicobacter pylori infection in rheumatoid arthritis: effect of drugs on prevalence and correlation with gastroduodenal lesions
Ishikawa et al.
Rheumatology (Oxford) 2002;41:72-77.
ABSTRACT | FULL TEXT  

NSAID Gastropathy: A New Understanding
Roth
Arch Intern Med 1996;156:1623-1628.
ABSTRACT  

Use of nonsteroidal anti-inflammatory drugs in cancer
Pace
Palliat Med 1995;9:273-286.
ABSTRACT  

Corticosteroids and peptic ulceration
Ellershaw and Kelly
Palliat Med 1994;8:313-319.
ABSTRACT  

Massive Gastrointestinal Bleeding Associated With Ketorolac Administration
Erstad and Neumayer
Journal of Pharmacy Practice 1992;5:xi-xii.
 

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs: A Meta-analysis
Gabriel et al.
ANN INTERN MED 1991;115:787-796.
ABSTRACT  

The Impact of Ulcerogenic Drugs on Surgery for the Treatment of Peptic Ulcer Disease
Bliss and Stabile
Arch Surg 1991;126:609-612.
ABSTRACT  

The Cost-effectiveness of Misoprostol
Roth
JAMA 1991;265:593-594.
ABSTRACT  

Cost-effectiveness of Misoprostol for Prophylaxis Against Nonsteroidal Anti-inflammatory Drug--Induced Gastrointestinal Tract Bleeding
Edelson et al.
JAMA 1990;264:41-47.
ABSTRACT  

Nonsteroidal Anti-inflammatory Drug Nephrotoxicity: Should We Be Concerned?
Stillman and Schlesinger
Arch Intern Med 1990;150:268-270.
ABSTRACT  

Economic Effects of Prophylactic Use of Misoprostol to Prevent Gastric Ulcer in Patients Taking Nonsteroidal Anti-inflammatory Drugs
Hillman and Bloom
Arch Intern Med 1989;149:2061-2065.
ABSTRACT  

Misoprostol Heals Gastroduodenal Injury in Patients With Rheumatoid Arthritis Receiving Aspirin
Roth et al.
Arch Intern Med 1989;149:775-779.
ABSTRACT  

Therapeutic Drug Monitoring in Patients With Ulcers
Itokazu and Danziger
Journal of Pharmacy Practice 1989;2:382-392.
 

Nonsteroidal Anti-Inflammatory Drugs: Gastropathy, Deaths, and Medical Practice
Roth
ANN INTERN MED 1988;109:353-354.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.